Literature DB >> 20424952

Baroreflex stimulation in antihypertensive treatment.

Jeremy G Taylor1, John D Bisognano.   

Abstract

Hypertension is a leading cause of morbidity and mortality worldwide. Despite the development of new medications, an alarmingly high proportion of patients are not reaching their target blood pressure goals, so nonpharmacologic therapies have been attracting more interest. Chronic baroreceptor stimulation of the carotid sinus has been shown to reduce blood pressure by inhibiting the sympathetic nervous system, particularly the renal sympathetic tone. This finding has led to the development of implantable carotid sinus stimulators, which have now been studied in both animals and humans, as a means for treating chronic hypertension. The enthusiasm for this modality has led to ongoing studies, which will provide more information on its safety and efficacy in patients with resistant hypertension. The early study results using baroreflex stimulation therapy are promising and suggest that it may play a significant role in controlling blood pressure in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424952     DOI: 10.1007/s11906-010-0106-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  30 in total

1.  Baroceptor function in chronic renal hypertension.

Authors:  J W MCCUBBIN; J H GREEN; I H PAGE
Journal:  Circ Res       Date:  1956-03       Impact factor: 17.367

2.  Prolonged activation of the baroreflex abolishes obesity-induced hypertension.

Authors:  Thomas E Lohmeier; Terry M Dwyer; Eric D Irwin; Martin A Rossing; Robert S Kieval
Journal:  Hypertension       Date:  2007-04-16       Impact factor: 10.190

Review 3.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.

Authors:  F Turnbull; B Neal; T Ninomiya; C Algert; H Arima; F Barzi; C Bulpitt; J Chalmers; R Fagard; A Gleason; S Heritier; N Li; V Perkovic; M Woodward; S MacMahon
Journal:  BMJ       Date:  2008-05-14

4.  Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure.

Authors:  Irving H Zucker; Johnnie F Hackley; Kurtis G Cornish; Bradley A Hiser; Nicholas R Anderson; Robert Kieval; Eric D Irwin; David J Serdar; Jacob D Peuler; Martin A Rossing
Journal:  Hypertension       Date:  2007-09-10       Impact factor: 10.190

5.  Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension.

Authors:  T E Lohmeier; J R Lohmeier; A Haque; D A Hildebrandt
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-10       Impact factor: 3.619

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

9.  Prolonged activation of the baroreflex produces sustained hypotension.

Authors:  Thomas E Lohmeier; Eric D Irwin; Martin A Rossing; David J Serdar; Robert S Kieval
Journal:  Hypertension       Date:  2004-01-05       Impact factor: 10.190

10.  What price for blood pressure control?

Authors:  Stephen C Textor
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-10       Impact factor: 3.738

View more
  3 in total

Review 1.  Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure.

Authors:  Michael Doumas; Charles Faselis; Costas Tsioufis; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

2.  Autocrine/paracrine modulation of baroreceptor activity after antidromic stimulation of aortic depressor nerve in vivo.

Authors:  Valter J Santana-Filho; Greg J Davis; Jaci A Castania; Xiuying Ma; Helio C Salgado; Francois M Abboud; Rubens Fazan; Mark W Chapleau
Journal:  Auton Neurosci       Date:  2014-02       Impact factor: 3.145

3.  Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy.

Authors:  Lufei Hu; Yinhong Chen; Xiaoyan Zhou; Maarten Hoek; Jason Cox; Ken Lin; Yang Liu; Wendy Blumenschein; Jeff Grein; Gayathri Swaminath
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.